NCT00592995View on ClinicalTrials.gov

Creatine Safety and Tolerability in Premanifest HD: PRECREST

PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions
Huntington Disease
Interventions
DRUG

Creatine monohydrate

10 to 30 grams daily

DRUG

Placebo

10 to 30 grams daily

Trial Locations (1)

02129

Massachusetts General Hospital, Charlestown

All Listed Sponsors
lead

Massachusetts General Hospital

OTHER

NCT00592995 - Creatine Safety and Tolerability in Premanifest HD: PRECREST | Biotech Hunter | Biotech Hunter